1. Immunotherapeutic targets in non-small cell lung cancer.
- Author
-
Sadeghirad, H, Bahrami, T, Layeghi, SM, Yousefi, H, Rezaei, M, Hosseini-Fard, SR, Radfar, P, Warkiani, ME, O'Byrne, K, Kulasinghe, A, Sadeghirad, H, Bahrami, T, Layeghi, SM, Yousefi, H, Rezaei, M, Hosseini-Fard, SR, Radfar, P, Warkiani, ME, O'Byrne, K, and Kulasinghe, A
- Abstract
Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.
- Published
- 2023